Company: Translate Bio, Inc.
Symbol: TBIO
Description: They are a leading messenger RNA, or mRNA, therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction
Trade Date: 6/28
Shares: 7.7 million
Price Range: $12.00-$14.00
Underwriter(s): Citigroup, Leerink Partners, Evercore ISI
Terms Added; 6-18-18
Business: They are a leading messenger RNA, or mRNA, therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Using their proprietary mRNA therapeutic platform, or MRT platform, they create mRNA that encodes functional proteins. They believe that the mRNA design, delivery and manufacturing capabilities of their MRT platform provide them with the most advanced platform for developing product candidates that deliver mRNA encoding functional proteins for therapeutic uses. Their mRNA is delivered to the target cell where the cell’s own machinery recognizes it and translates it, restoring or augmenting protein function to treat or prevent disease. They believe that their MRT platform is broadly applicable across multiple diseases in which the production of a desirable protein can have a therapeutic effect. They are initially focused on restoring the expression of intracellular and transmembrane proteins, areas that have eluded conventional protein therapeutics, in patients with genetic diseases where there is high unmet medical need. They are developing their lead MRT product candidate for the lung, MRT5005, for the treatment of cystic fibrosis, or CF, for which they initiated a Phase 1/2 clinical trial in May 2018. They are developing their lead MRT product candidate for the liver, MRT5201, for the treatment of ornithine transcarbamylase, or OTC, deficiency, for which they plan to initiate a Phase 1/2 clinical trial in the first half of 2019. They believe that their MRT platform is distinct from other mRNA-based technologies and has the potential to provide clinical benefits by transforming life-threatening illnesses into manageable chronic conditions.
Insider Buying:Certain of their existing stockholders and their affiliated entities have indicated an interest in purchasing an aggregate of approximately $50 million in shares of their common stock in this offering at the initial public offering price and on the same terms and conditions as the other purchasers in this offering.
Book-Building Status: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.
IPO Boutique subscription clients receive daily updates on this critical information.
Conclusion: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a track record with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance to showcase the value of IPO Boutique’s service.
Indicate with confidence, SUBSCRIBE today.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish